Nonalcoholic Steatohepatitis Treatment Market is Witnessing Massive Traction as Ionis Pharmaceuticals, Inc. Continues its R&D with another Investigational Drug

 

Nonalcoholic Steatohepatitis (NASH) is an inflammation of the lower portion of the small intestine that includes the stomach and the duodenum. It is the most common digestive disease in the United States and is one of several types of the disease known as a fatty liver. Although the exact cause of this condition is not known, it is believed to be related to excessive amounts of insulin resistance or the lack of a sufficient level of the enzyme lipase. This condition does not present any symptoms but exists until the liver is able to properly digest and process insulin and lipid molecules. The treatment options for NASH are usually limited to anti-lipase agents and the restriction of carbohydrate intake. However, recently researchers have discovered that the consumption of green tea may be beneficial in treating and preventing the symptoms of NASH.

 

Rising incidence of nonalcoholic fatty liver disease (NAFLD) is expected to drive growth of the global nonalcoholic steatohepatitis treatment market during the forecast period. According to the American Liver Foundation (ALF), around 100 million individuals in the U.S. are expected to have NAFLD. According to the BMJ Journals, cases of NAFLD increasing from 391.2 million in 1990 to 882.1 million in 2017. According to the same source, the prevalence rate increased from 8.2% to 10.9% during the same period. Nonalcoholic steatohepatitis is a part of NAFLD and thus, the demand for treatment options is increasing rapidly. Hence, these factors are expected to drive growth of the global nonalcoholic steatohepatitis market during the forecast period. Furthermore, continuous research and development activities are expected to boost the global nonalcoholic steatohepatitis market growth over the forecast period.

However, a lack of effective medications and treatment options is expected to restrain growth of the global nonalcoholic steatohepatitis market during the forecast period. Among regions, North America is expected to witness significant growth in the global nonalcoholic steatohepatitis market during the forecast period. This is owing to proactive government initiatives and increasing cases of chronic diseases such as cancer and diabetes across the region. According to the American Diabetes Association (ADA), in 2018, around 34.2 million Americans had diabetes. Furthermore, Asia Pacific is expected to register a robust growth rate over the forecast period, owing to increasing R&D expenditure by key market players.

Key competitors operating in the global nonalcoholic steatohepatitis market are GE Healthcare, Agilent Technologies, Abbott Diagnostics, EUSA Pharma, BioCurex, Inc., Eli Lilly & Co., Biomarker Technologies, LLC, CytoCore, Inc., Ionis Pharmaceuticals, Inc., and Bruker Daltonics, Inc.

For instance, in November 2020, Ionis Pharmaceuticals, Inc. introduced the third investigational antisense medicine to treat nonalcoholic steatohepatitis (NASH).